Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Forge Announces Visible Gold & Continued Porphyry Mineralization at Alotta Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(6242)
•••
retiredcf
X
Post by
retiredcf
on Nov 22, 2023 8:07am
Ink Research
Today, we revisit two healthcare stocks, Knight Therapeutics (GUD), last featured here on June 9th, 2022, and Cipher Pharmaceuticals (CPH), last featured here on September 18th. Knight
...more
(5001)
•••
nozzpack
X
Post by
nozzpack
on Nov 16, 2023 8:45am
Cipher to buyback 10% of the float
Cipher Pharma arranges NCIB to buy back up to 10% float 2023-11-15 17:08 ET - News Release An anonymous director reports CIPHER PHARMACEUTICALS ANNOUNCES NORMAL COURSE
...more
(5001)
•••
nozzpack
X
Post by
nozzpack
on Nov 14, 2023 8:03am
Peer based Valuation Is $12
I use Biostent ( T.RX ) which is a very close sibling of CPH. Great balance sheet.....but not as good as as CPH. Similar drug suites...but not as good as CPH as RX shows no growth . RX trades at 20
...more
(5001)
•••
nozzpack
X
Comment by
nozzpack
on Nov 10, 2023 10:35am
RE:Spectacular Earnings Numbers..Virtual Cash Cow
So, it's worth $2.25 per share on its cash alone and no debt. Over the past 3 quarters, it has been free cash flowing over $6 million cad per quarter. Thats about $25 million or $1 per share
...more
(5001)
•••
nozzpack
X
Post by
nozzpack
on Nov 10, 2023 10:11am
Spectacular Earnings Numbers..Virtual Cash Cow
Cipher earns $7.03-million (U.S.) in Q3 2023 2023-11-09 17:33 ET - News Release Mr. Craig Mull reports CIPHER
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 27, 2023 7:01am
New Press Release - Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call
MISSISSAUGA, ON, Oct. 27, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the third quarter of 2023 on Thursday, November 9, 2023. The Company will also host a conference call on Friday, November 10...
read article.
(1590)
•••
lscfa
X
Comment by
lscfa
on Oct 12, 2023 10:10am
RE:New Press Release - Cipher Pharmaceuticals Announces Final Results of Substantial Issuer Bid
Huge tax bill to shareholders who tendered.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 12, 2023 9:58am
New Press Release - Cipher Pharmaceuticals Announces Final Results of Substantial Issuer Bid
MISSISSAUGA, ON, Oct. 12, 2023/CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company"), today announced the final results of its substantial issuer bid (the "Offer"), which expired at 5:00 p.m. (Eastern Time) on October 11, 2023. The Company expects to take up and pay for 1,290...
read article.
(14)
•••
drewmumaw
X
Post by
drewmumaw
on Oct 11, 2023 1:48pm
Enrollment complete for the 2nd North American Phase 3 study
According to this Swedish financial news outlet: https://www.redeye.se/research/946026/moberg-pharma-completed-enrollment-for-the-phase-3-study-in-the-us According to this
...more
(14)
•••
drewmumaw
X
Comment by
drewmumaw
on Oct 06, 2023 3:11pm
RE:Comprehensive Valuation Report on Cipheras of August 31 2023
Does management really believe that a lot of shareholders will tender their shares with that kind of growth ? I hope so. The overhead for this auction is costing the company $400k. From page 41:
...more
(7)
•••
stef1234
X
Post by
stef1234
on Oct 03, 2023 10:00pm
Comprehensive Valuation Report on Cipheras of August 31 2023
A very interesting reading found in Issuer Bid Circular issued in September. You can find a Comprehensive valuation report on Cipher in the last 40 pages of the issuer bid circular made by Evans
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 03, 2023 7:02am
New Press Release - Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid
MISSISSAUGA, ON, Oct. 3, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company"), today provided a reminder of its previously announced substantial issuer bid (the "Offer" or "SIB") under which the Company has offered to purchase for cancellation up to $6,000,000 of its...
read article.
(14)
•••
drewmumaw
X
Comment by
drewmumaw
on Sep 26, 2023 5:07pm
RE:Cipher share price is ahead of Knight Therapeutics this a.m.
My initial reaction to the Dutch auction was that it was another way—in addition to the NCIB—to shake out paper hands before they make an acquisition that may lift the share price significantly higher
...more
(5)
•••
PitchinPennies
X
Post by
PitchinPennies
on Sep 25, 2023 12:15pm
Cipher share price is ahead of Knight Therapeutics this a.m.
Cipher passed Knight? I have to admit I didn't see this happening -- ever. Probably reflects more on what Knight failed to accomplish with its great resources, and less on Craig Mull's having
...more
(2)
•••
ValueCat
X
Post by
ValueCat
on Sep 21, 2023 1:20pm
Big bids
Trading massively above the range. bump on the way?
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Canadian clean tech company pioneering the upcycling of used motor oil into high value Group III base oils
A Canadian mineral company at the crossroads of electrification and defense
Gold rush 2025: Why Desert Gold Ventures Inc. is now on the brink of a historic revaluation!
Maiden Resource Estimate of 54 Moz at 284 gpt Silver, Highlights High-Grade Potential at Columba